Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC).’ The study aims to evaluate the effectiveness of cemiplimab, an immune-boosting drug, compared to standard surgery in treating early-stage CSCC. This research is significant as it explores less invasive treatment options for skin cancer.
The intervention being tested is cemiplimab, a drug designed to enhance the immune system’s ability to fight cancer by targeting the PD-1 protein on immune cells. The study compares this drug to the standard surgical treatment.
The study design is interventional with a randomized allocation and parallel intervention model. It is unmasked, meaning both researchers and participants know which treatment is being administered. The primary aim is treatment-focused.
The study began on January 2, 2025, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on June 24, 2025, indicating ongoing recruitment and progress.
This study could impact Regeneron’s stock performance positively if cemiplimab proves effective, offering a new treatment avenue for CSCC. It may also influence investor sentiment by showcasing Regeneron’s commitment to innovative cancer treatments. Competitors in the oncology space will be closely monitoring these developments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.